FindTrial
Sign In

A clinical intervention study of high-definition transcranial direct current stimulation targeting the cerebellum in schizophrenia

The effects of high-definition transcranial direct current stimulation targeting the cerebellum on reward processing and negative symptoms in schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102710
Enrollment
Unknown
Registered
2025-05-19
Start date
2024-11-05
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Active Stimulation Group:Active high-definition transcranial direct current stimulation (HD-tDCS) targeting the cerebellum
Sham Stimulation Group:Sham high-definition transcranial direct current stimulation (HD-tDCS) targeting the cerebellum

Sponsors

Institute of Psychology, Chinese Academy Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosis of schizophrenia in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (APA, 2013); 2.18~65 years old; 3.At least a junior high school education; 4.Participants must be willing to engage in and cooperate with the testing process.

Exclusion criteria

Exclusion criteria: 1.Comorbid with other mental disorders (such as anxiety disorder, obsessive-compulsive disorder, etc.); 2.History of drug addiction or substance abuse; 3.History of brain trauma or nervous system disease; 4.Receiving MECT within the past 8 weeks and transcranial magnetic stimulation (TMS) or other tDCS/tACS within 4 weeks; 5.Changing the type of drug within 2 weeks; 6.In the acute phase of the disease; 7.Had contraindications to tDCS experiment (history or family history of epilepsy, current use of epilepsy drugs, metal implants in the head, scalp inflammation or injury, pregnancy, cardiovascular problems).

Design outcomes

Primary

MeasureTime frame
Global Assessment of Psychopathology;Motivation and Pleasure Domain of Negative Symptoms;Global Assessment of Negative Symptoms;—

Secondary

MeasureTime frame
Anxiety State;Depression State;Anticipatory and Consummatory Pleasure;Reward Processing Activation/Connectivity;Interpersonal Pleasure;Anhedonia;Antipsychotic Side Effects;Motivation and Pleasure;Pleasure Capacity;IQ;Reward Sensitivity;Alexithymia;History of Childhood Trauma;Cerebellar-Reward Network Functional Connectivity;HD-tDCS Side Effects;Social Functioning;Depression Symptoms;Affect State;—

Countries

China

Contacts

Public ContactChen Chuqiao

Institute of Psychology, Chinese Academy Sciences

rckchan@psych.ac.cn+86 10 64836274

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026